

INFECTIOUS BOVINE RHINOTRACHEITIS/ INFECTIOUS PUSTULAR VULVOVAGINITIS

SUMMARY

Description of disease: *Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis (IBR/IPV), caused by bovine herpesvirus 1 (BoHV-1), is a disease of domestic and wild cattle. The virus is distributed world-wide, but has been eradicated from a number of European countries and others have active eradication programmes.*

The disease is characterised by clinical signs of the upper respiratory tract, such as a (muco)purulent nasal discharge, hyperaemia of the muzzle (red nose disease) and by conjunctivitis. Signs of general illness are fever, depression, inappetence, abortions and reduced milk yield. The virus can also infect the genital tract and cause pustular vulvovaginitis and balanoposthitis. Post-mortem examinations reveal rhinitis, laryngitis and tracheitis. Mortality is low, and most infections run a subclinical course. Secondary bacterial infections can lead to more severe respiratory disease, and BoHV-1 could play a role in multifactor diseases such as 'shipping fever'.

Identification of the agent: *The virus can be isolated from nasal or genital swabs from animals with respiratory signs, vulvovaginitis or balanoposthitis, taken during the acute phase of the infection, and, in severe cases, from various organs collected at post-mortem. Following infection, BoHV-1 may persist in infected animals in a latent state in sensory neurons, e.g. in the trigeminal or sacral ganglia. The virus can be reactivated and this results in virus shedding (re-excretion) without exhibition of clinical disease. Because of this latency phenomenon, antibody-positive animals have to be classified as infected with BoHV-1 (with two exceptions: serological responses induced by vaccination with an inactivated vaccine or by colostral antibodies).*

For virus isolation, various cell cultures of bovine origin are used, for example, secondary lung or kidney cells or the Madin–Darby bovine kidney cell line. The virus produces a cytopathic effect in 2–4 days. It is identified by neutralisation or antigen detection methods using monospecific antisera or monoclonal antibodies. BoHV-1 isolates can be further subtyped by DNA restriction enzyme analysis into subtypes 1.1 and 1.2. BoHV-1.2 isolates can be further differentiated into 2a and 2b. Development of rhinotracheitis or vulvovaginitis/balanoposthitis depends more on the route of infection than on the subtype of the virus. The virus previously referred to as BoHV-1.3, a neuropathogenic agent, is now classified as BoHV-5.

For virus DNA detection, the polymerase chain reaction (PCR) technique is increasingly used in routine diagnosis especially the real-time PCR.

Serological tests: *The virus neutralisation test and various enzyme-linked immunosorbent assays (ELISA; indirect or blocking) are most widely used for antibody detection. With the ELISAs, antibodies can be detected in serum or plasma, and with lower sensitivity in milk or bulk milk samples. The use of a gE-antibody-ELISA makes it possible to distinguish field virus infected cattle from cattle vaccinated with a gE-deleted marker vaccine (DIVA strategy).*

Requirements for vaccines: *Inactivated and attenuated live vaccines are available. The vaccines protect cattle clinically in case of infection and markedly reduce the subsequent shedding of field virus. Although vaccination may not prevent field virus infection of individual animals, spreading of wild-type virus in infected herds is efficiently reduced. The vaccines must not induce disease, abortion, or any local or systemic reaction, and must be genetically stable. BoHV-1 glycoprotein E deleted mutant marker vaccines are now generally available (live or inactivated) and can be used as part of a DIVA strategy.*

A. INTRODUCTION

Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis (IBR/IPV), caused by bovine herpesvirus 1 (BoHV-1), is a disease of domestic and wild cattle. BoHV-1 is a member of the genus *Varicellovirus* in the subfamily *Alphaherpesvirinae*, which belongs to the *Herpesviridae* family, order *Herpesvirales*. The viral genome consists of double-stranded DNA that encodes for about 70 proteins, of which 33 structural and more than 15 nonstructural proteins have been identified. The viral glycoproteins, which are located in the envelope on the surface of the virion, play an important role in pathogenesis and immunity. BoHV-1 can be differentiated into subtypes 1.1, 1.2a and 1.2b (Metzler *et al.*, 1985). The BoHV-1.2 subtypes may be less virulent than subtype 1.1 (Edwards *et al.*, 1990). The former BoHV-1.3, which may act as a neuropathogenic agent in calves, has been reclassified as BoHV-5 (Magyar *et al.*, 1993). BoHV-1 shares antigenic and genetic close relationships with other ruminant alphaherpesviruses: BoHV-5, caprine herpesvirus 1, cervid herpesvirus 1 (red deer), cervid herpesvirus 2 (reindeer), bubaline herpesvirus 1 and elk herpesvirus 1 (Thiry *et al.*, 2006).

After an incubation period of 2–4 days, serous nasal discharge, salivation, fever, inappetence, and depression become evident. Within a few days the nasal and ocular discharges change to mucopurulent. Where natural mating is practised, genital infection can lead to pustular vulvovaginitis or balanoposthitis. However, most infections run a very mild or subclinical course (Van Oirschot *et al.*, 1993). Uncomplicated cases of respiratory or genital disease caused by BoHV-1 last about 5–10 days. Secondary bacterial or viral agents may contribute to a multifactor disease complex resulting in severe respiratory disease of young animals ('shipping' or 'crowding fever').

After infection via the airborne route, BoHV-1 replicates to high titres in mucous membranes of the upper respiratory tract and in the tonsils. Subsequently, the virus disseminates to conjunctivae and reaches the trigeminal ganglia by neuronal axonal transport. After genital infection, BoHV-1 replicates in the mucous membranes of the vagina or prepuce, and becomes latent in the sacral ganglia. The viral DNA remains in the neurons of the ganglia, probably for the entire life of the host (status of latency). Stress, such as transport and parturition, but also the application of corticosteroids can induce reactivation of the latent infection. Consequently, the virus may switch between latent and lytic infection and may be shed intermittently into the environment and spread to contact animals.

BoHV-1 infection elicits an antibody response and a cell-mediated immune response within 7–14 days. The immune response is presumed to persist life-long, although it may fall below the detection limit of some tests after a number of years. Maternal antibodies are transferred via colostrum to the young calf, which is consequently protected against BoHV-1-induced clinical disease (Mechor *et al.*, 1987). Maternal antibodies have a biological half-life of about 3 weeks, but may be detected occasionally in animals for several months.

The virus is distributed worldwide, with the exception of the BoHV-1-free countries, paralleling the distribution of domestic cattle. Other *Artiodactyla* (e.g. goats, sheep, water buffaloes, camelids) may be infected with BoHV-1. After infection, nasal viral shedding is detected for 5–14 days, with peak titres of 10^8 – 10^{10} TCID₅₀ (50% tissue culture infective doses) per ml of nasal secretion. The semen of an infected bull may contain BoHV-1, and the virus can thus be transmitted by natural mating and artificial insemination (Parsonson & Snowdon, 1975).

Vaccines usually prevent the development of clinical signs and markedly reduce the shedding of virus after infection, but do not completely prevent infection. Several eradication campaigns have been carried out or are currently running in different countries including test-and-removal programmes or vaccination campaigns (see Section C).

BoHV-1 infection may be suspected on the basis of clinical, pathological and epidemiological findings. However, to make a definite diagnosis, laboratory examinations (serology or virus detection) are required. A complete diagnostic procedure in the laboratory is aimed at detecting the causative virus (or viral components) and the specific antibodies they induce. Nevertheless, because of latent infection induced by BoHV-1, detection of antibodies could be sufficient for the determination of the BoHV-1 status of individual animals.

B. DIAGNOSTIC TECHNIQUES

Table 1. Test methods available for the diagnosis of BoHV-1 and their purpose

Method	Purpose					
	Population freedom from infection	Individual animal freedom from infection prior to movement	Contribute to eradication policies	Confirmation of clinical cases	Prevalence of infection – surveillance	Immune status in individual animals or populations post-vaccination
Identification of the agent¹						
Virus isolation	–	+ ²	+	++	–	–
Real-time PCR	–	+ ²	+	+++	–	–
Detection of immune response						
ELISA	+++	+++	+++	++	+++	+++
VN	++	++	++	+	++	++

Key: +++ = recommended for this purpose; ++ recommended but has limitations;
+ = suitable in very limited circumstances; – = not appropriate for this purpose.

PCR = polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay; VN = virus neutralisation.

1. Identification of the agent

1.1. Collection and processing of specimens

Nasal swabs, preferably foam or flocked swabs, are collected from several (from five to ten) affected cattle in the early phase of the infection. These cattle still have serous rather than mucopurulent nasal discharge. In cases of vulvovaginitis or balanoposthitis, swabs are taken from the genitals. The swabs should be vigorously rubbed against the mucosal surfaces. The prepuce can also be washed with saline; the washing fluid is then collected. The specimens are suspended in transport medium (cell culture medium containing antibiotics and 2–10% BoHV-1-free fetal bovine serum to protect the virus from inactivation), cooled at 4°C, and rapidly submitted to the laboratory.

During necropsy, mucous membranes of the respiratory tract, and samples of the tonsil, lung and bronchial lymph nodes are collected for virus detection. In cases of abortion, the fetal liver, lung, spleen, kidney and placental cotyledons are examined. Samples should be kept on ice and sent to the laboratory as quickly as possible.

After arrival at the laboratory, swabs are agitated at room temperature for 30 minutes in the transport medium to elute virus. Following removal of the swabs, the transport medium is clarified by centrifugation at 1500 *g* for 10 minutes. Tissues are homogenised to a 10–20% (w/v) suspension in cell culture medium before centrifugation at 1500 *g* for 10 minutes. The supernatants of these specimens are filtered through 0.45 µm filters and used for virus isolation.

The isolation of virus from semen needs some special adaptations, because the seminal fluid contains enzymes and other factors that are toxic to the cells and inhibit viral replication (see below).

1.2. Virus isolation

For virus isolation, bovine cells of various origins can be used. Primary or secondary bovine kidney, lung or testis cells, cell strains derived from bovine fetal lung, turbinate or trachea, and established cell lines, such as the Madin–Darby bovine kidney cell line (MDBK), are suitable for BoHV-1 propagation. Cell cultures can be grown in glass or plastic tubes, plates or dishes. When 24-well plastic plates are

¹ A combination of agent identification methods applied on the same clinical sample is recommended.

² Method particularly applicable to testing of semen.

used, a 100–200 µl volume of the supernatants described above is inoculated into these cell cultures. After a 1-hour adsorption period, the cultures are rinsed and maintenance medium is added. The serum used as a medium supplement in the maintenance medium should be free of antibodies against BoHV-1. The cell cultures are observed daily for cytopathic effect (CPE), which usually appears within 3 days after inoculation. It is characterised by grape-like clusters of rounded cells gathered around a hole in the monolayer; sometimes giant cells with several nuclei may be observed. Experience is needed to recognise this characteristic appearance. When, after 7 days, no CPE has appeared, a blind passage must be made. The cell culture is freeze–thawed and clarified by centrifugation, and the supernatant is used for inoculation of fresh monolayers (Brunner *et al.*, 1988; Edwards *et al.*, 1983).

To identify the recovered virus as BoHV-1, the supernatant of the culture should be neutralised with a monospecific BoHV-1 antiserum or neutralising monoclonal antibody (MAb). For this purpose, serial tenfold dilutions of the test supernatant are made, and to each dilution monospecific BoHV-1 antiserum or negative control serum is added. Following incubation at 37°C for 1 hour, the mixtures are inoculated into cell cultures; 3–5 days later, the neutralisation index is calculated. The neutralisation index is the virus titre (in log₁₀) in the presence of negative control serum minus the virus titre in the presence of specific antiserum. If the neutralisation index is greater than 1.5, the isolate may be considered to be BoHV-1. To shorten the virus isolation procedure, two specimens may be inoculated into cell culture: one that has been pre-incubated with monospecific antiserum and another that has been preincubated with negative control serum. If the CPE is inhibited by the monospecific antiserum, the isolate can be considered to be BoHV-1, although definitive confirmation would require molecular characterisation to distinguish it from related ruminant alphaherpesviruses.

An alternative method of virus identification is the direct verification of BoHV-1 antigen in cells around the CPE by an immunofluorescence or immunoperoxidase test (Kaashoek *et al.*, 1994) with conjugated monospecific antiserum or MAb. Furthermore, the supernatant can be used as template for restriction endonuclease fragment length polymorphism (RFLP) (see Section B.1.4) and polymerase chain reaction (PCR) analyses (see Section B.1.3).

1.2.1. Virus isolation from semen

0.05 to 0.1 ml of raw semen should be tested with two passages in cell culture. Raw semen is generally cytotoxic and should be prediluted (e.g. 1/10) before being added to cell cultures. A similar problem may sometimes arise with extended semen. For extended semen, an approximation should be made to ensure that the equivalent of a minimum of 0.1 ml raw semen is examined (e.g. a minimum of 0.5 ml extended semen). Multiple diluted samples may need to be tested with this procedure to reach a volume equivalent to 0.1 ml raw semen (e.g. 5 × 1 ml of a 1/10 diluted sample of extended semen). A suitable test procedure is given below. See also Brunner *et al.* (1988).

1.2.1.1. Test procedure

- i) Dilute 200 µl fresh semen in 2 ml fetal bovine serum (free from antibodies against BoHV-1) with antibiotics.
- ii) Mix vigorously and leave for 30 minutes at room temperature.
- iii) Inoculate 1 ml of the semen/serum mixture into a monolayer of susceptible cells (see virus isolation above) in a six-well tissue culture plate.
- iv) Incubate the plates for 1 hour at 37°C.
- v) Remove the mixture, wash the monolayer twice with 5 ml maintenance medium, and add 5 ml maintenance medium to each well.
- vi) Include BoHV-1 negative and positive controls in the test. Special caution must be taken to avoid accidental contamination of test wells by the positive control, for example always handling the control last, and using separate plates.
- vii) Observe plates under a microscope daily for the appearance of a CPE. If a CPE appears, confirmatory tests for BoHV-1 are made by specific neutralisation or immunolabelling methods (see above).
- viii) If there is no CPE after 7 days, the cultures are frozen and thawed, clarified by centrifugation, and the supernatant is used to inoculate fresh monolayers.
- ix) The sample is considered to be negative, if there is no evidence of a CPE after 7 days' incubation of the passaged cultures.

1.3. Nucleic acid detection

During the past decade, various methods for the detection of BoHV-1 DNA in clinical samples have been described, including DNA–DNA hybridisation and PCR. PCR is increasingly being used in routine diagnostic submissions (Moore *et al.*, 2000). Compared with virus isolation, PCR has the primary advantages of being more sensitive and more rapid: it can be performed in 1–2 days. It is also possible to detect episomal DNA of non-replicating virus in sensory ganglia (Van Engelenburg *et al.*, 1993), such as the trigeminal ganglion, in the latent phase of infection. The disadvantage is that PCR analyses are prone to contamination and therefore precautions have to be taken to prevent false-positive results. Risk of contamination is markedly reduced by new PCR techniques, such as real-time quantitative PCR (see below) (Abril *et al.*, 2004; Lovato *et al.*, 2003; Wernike *et al.*, 2011) and the PCR method is recommended in all cases for direct BoHV-1 detection.

So far, PCR has been used mainly to detect BoHV-1 DNA in artificially (Kramps *et al.*, 1993) or naturally (Van Engelenburg *et al.*, 1993) infected semen samples. It is important to thoroughly optimise the PCR conditions, including the preparation of the samples, the concentration of test components e.g. primers and polymerase, and the cycle programmes. The target region for amplification must be present in all BoHV-1 strains, and its nucleotide sequence must be conserved. The TK, gB, gC, gD and gE genes have been used as targets for PCR amplification. In addition, PCRs based on detection of gE sequences can be used to differentiate between wild-type virus and gE-deleted vaccine strains (Fuchs *et al.*, 1999; Schynts *et al.*, 1999; Wernike *et al.*, 2011). Discrimination between infection with virulent IBR strains and infection with live attenuated (non-marker) strains may not be easily achievable with the PCR technique, and RFLP or high throughput sequencing (HTS) can be used for this purpose. Specific PCRs have been developed that are able to discriminate between BoHV-1, BoHV-5 and other related alphaherpesviruses (Ashbaugh *et al.*, 1997; Ros *et al.*, 1999).

Experimentally, PCR was found to be more sensitive than virus isolation: in egg yolk-extended semen samples obtained from experimentally infected bulls, PCR detected five times as many positives as did virus isolation (Van Engelenburg *et al.*, 1995). The detection limit of validated PCR assays amounts to only a few genome copies per PCR reaction. Nevertheless, false-negative results cannot be excluded. To identify possible false-negative results, it is recommended to spike an internal control template into the reaction tube of the semen sample to be amplified by the same primers. Such a control template may be constructed by inserting, for example, a 100 base-pair fragment into the target region. This control template also makes it possible to semi-quantify the amount of DNA that is detected (Ros *et al.*, 1999; Van Engelenburg *et al.*, 1993). When using an internal control, extensive testing is necessary to ensure that PCR amplification of the added internal control does not compete with the diagnostic PCR and thus lower the analytical sensitivity (see also Chapter 1.1.6 *Principles and methods of validation of diagnostic assays for infectious diseases*). DNA extraction and quality of the DNA preparations can also be controlled by amplification of cellular sequences (housekeeping genes, Wernike *et al.*, 2011) or by addition of 'artificial' DNA sequences prior to extraction procedures (e.g. green fluorescent protein gene, non-BoHV-related viruses) as internal controls. To enhance the sensitivity and specificity of the BoHV-1 PCR, real-time PCR systems are the methods of choice.

1.3.1. Real-time polymerase chain reaction

The following real-time PCR test method has been developed to detect BoHV-1 in extended bovine semen destined for trade. The method has been validated according to chapter 1.1.6, and includes a comprehensive international inter-laboratory comparison involving six collaborating laboratories with specialist status in IBR testing (Wang *et al.*, 2008).

A number of studies have shown that PCR assays are more sensitive than virus isolation (Smits *et al.*, 2000; Van Engelenburg *et al.*, 1995; Vilcek *et al.*, 1994; Wang *et al.*, 2008; Wiedmann *et al.*, 1993). Real-time PCR has been used for the detection of BoHV-1 and BoHV-5 in experimentally infected cattle and mice (Abril *et al.*, 2004; Lovato *et al.*, 2003) and a series of conventional PCR assays have been used for the detection of BoHV-1 DNA in artificially or naturally infected bovine semen samples (Deka *et al.*, 2005; Grom *et al.*, 2006; Masri *et al.*, 1996; Van Engelenburg *et al.*, 1993; Weiblen *et al.*, 1992; Wiedmann *et al.*, 1993; Xia *et al.*, 1995). Conventional detection of amplified PCR products relies on gel electrophoresis analysis (Rola *et al.*, 2003). Sequence-specific primers have been selected to amplify different parts of conserved glycoprotein genes of the BoHV-1 genome, including glycoprotein B (gB) gene (Grom *et al.*, 2006; Santurde *et al.*, 1996), gC gene (Smits *et al.*, 2000; Van Engelenburg *et al.*, 1995), gD gene (Smits *et al.*, 2000; Wiedmann *et al.*, 1993), gE gene (Grom *et al.*, 2006), and the thymidine kinase (tk) gene (Moore *et al.*, 2000; Yason *et al.*, 1995). Furthermore, a triplex real-time PCR for the detection of BoHV-1 gD and gE genes together with a house-keeping gene was validated and reported in 2011 (Wernike *et al.*, 2011). This PCR also allows the easy and fast differentiation of BoHV-1-field strains from gE-deleted vaccine strains.

The real-time PCR described here uses a pair of sequence-specific primers for amplification of target DNA and a 5'-nuclease oligoprobe for detection of amplified products. The oligoprobe is a single, sequence-specific oligonucleotide, labelled with two different fluorophores, the reporter/donor 5-carboxyfluorescein (FAM) at the 5' end, and the acceptor/quencher 6-carboxytetramethylrhodamine (TAMRA) at the 3' end. This real-time PCR assay is designed to detect viral DNA of all BoHV-1 strains, including subtype 1 and 2, from extended bovine semen. The assay selectively amplifies a 97 base-pair sequence of the glycoprotein B (gB) gene. Details of the primers and probes are given in the protocol outlined below.

1.3.1.1. Sample preparation, equipment and reagents

- i) The samples used for the test are, typically, extended bovine semen stored in liquid nitrogen. The semen samples can be transported to the laboratory in liquid nitrogen, or shipped at 4°C, and stored in liquid nitrogen or at –70°C (for long-term storage) or 4°C (for short-term storage). Storing semen at 4°C for a short period (up to 7 days) does not affect PCR test result.
- ii) Three straws from each batch of semen should be processed. Duplicate PCR amplifications should be carried out for each DNA preparation (six amplifications in total) to ensure the detection of DNA in samples containing low levels of virus.
- iii) The real-time PCR assay described here involves two separate procedures. Firstly, BoHV-1 DNA is extracted from semen using Chelex-100 chelating resin, along with proteinase K and DL-dithiothreitol (DTT). The second procedure is the PCR analysis of the extracted DNA template in a real-time PCR reaction mixture. A number of commercial real-time PCR amplification kits are available and any particular kit selected needs to be compatible with the chosen real-time PCR platform. The required primers and probes can be synthesised by various commercial companies.

1.3.1.2. Extraction of DNA

- i) In a screw top 1.5 ml tube, add:

Chelex 100 sodium (10% w/v in distilled deionised water)	100 µl
Proteinase K (10 mg/ml)	11.5 µl
DL-dithiothreitol (1 M)	7.5 µl
Nuclease-free water	90 µl
Semen sample	10 µl

 Mix gently by pipetting³.
- ii) The samples are incubated at 56°C for 30 minutes and then vortexed at high speed for 10 seconds.
- iii) Subsequently, the tubes are incubated in a boiling water bath for 8 minutes and then vortexed at high speed for 10 seconds.
- iv) The tubes are centrifuged at 10,000 **g** for 3 minutes.
- v) The supernatant⁴ is transferred into a new microtube and can be used directly for PCR, or stored at –20°C.

1.3.1.3. Preparation of reagents

The manufacturer's instructions should be followed for application and storage of the real-time PCR reaction mixture.

Working stock solutions for primers and probe are made with nuclease-free water at the concentration of 4.5 µM and 3 µM, respectively. The stock solutions are stored at –20°C and the probe solution should be kept in the dark. Single-use aliquots can be prepared to limit freeze–thawing of primers and probes and extend their shelf life.

3 It is important that the Chelex 100 solution is homogeneous while pipetting, as Chelex 100 sodium is not soluble. This can be achieved by putting the vessel containing Chelex-100 solution on a magnetic stirrer while pipetting.

4 Some DNA samples can become cloudy and a thin white membrane may form occasionally after freezing and thawing. This appears to have no influence on the PCR performance. No heating or re-centrifuging of the samples is necessary.

1.3.1.4. Real-time PCR test procedurei) *Primers and probe sequences*

Selection of the primers and probe are outlined in Abril *et al.* (2004) and described below.

Primer gB-F: 5'-TGT-GGA-CCT-AAA-CCT-CAC-GGT-3' (position 57499–57519 GenBank®, accession AJ004801)

Primer gB-R: 5'-GTA-GTC-GAG-CAG-ACC-CGT-GTC-3' (position 57595–57575 GenBank®, accession AJ004801)

Labelled Probe: 5'-FAM-AGG-ACC-GCG-AGT-TCT-TGC-CGC-TAMRA-3' (position 57525–57545 GenBank®, accession AJ004801)

ii) *Preparation of reaction mixtures*

The PCR reaction mixtures are prepared in a separate laboratory room. For each PCR test, appropriate controls should be included. As a minimum, a no template control (NTC, reagents only), appropriate negative controls, i.e. 1 per 10 test samples, and two positive controls (moderate and weak positive) should be included. Each test sample and control is tested in duplicate. The PCR amplifications are carried out in a volume of 25 µl.

- a) PCR reagent mixtures are added in a clean room (no viral cultures, DNA extracts or post-amplification products should be handled here)

2 × real-time PCR reaction mixture	12.5 µl
ROX reference dye (optional)	0.5 µl
Forward primer (gB-F, 4.5 µM)	1 µl
Reverse primer (gB-R, 4.5 µM)	1 µl
Probe (3 µM)	1 µl
Nuclease free water	4 µl

- b) 5 µl of the DNA template are added to the PCR reagent mixture to a final volume of 25 µl. DNA samples are prepared and added to the PCR mix in a separate room.

iii) *Real-time polymerase chain reaction*

The PCR tubes are placed in the real-time PCR detection system in a separate, designated PCR room. The PCR detection system is programmed for the test as follows:

PCR Reaction Parameters (may vary with different PCR platforms)

One cycle: Hold 50°C	2 minutes
One cycle: Hold 95°C	2 minutes
45 cycles: Hold 95°C	15 seconds
Hold 60°C	45 seconds

iv) *Analysis of real-time PCR data*

The threshold level is usually set according to the manufacturers' instructions for the selected analysis software used. Alternatively, virus isolation negative semen samples, from seronegative animals, can be run alongside to determine the background signal associated with the detection system used.

1.3.1.5. Interpretation of resultsi) *Test controls*

Positive and negative controls, as well as reagent controls, should be included in each PCR test. Negative semen, from seronegative bulls, can be used as a negative control. Positive semen from naturally infected bulls is preferable as a positive control. However, this might be difficult to obtain. Alternatively, positive controls can be derived from negative semen spiked with defined quantities of BoHV-1 virus.

ii) *Test results*

Positive result: Any sample that has a cycle threshold (Ct) value equal or less than 45 associated with an amplification curve is regarded as positive. The positive control should have a Ct value within an acceptable range (± 3 Ct values) as previously determined by

repeatability testing. To minimise the risk of contamination by the positive control, a dilution resulting in a Ct value of about 30 to 33 should be used.

Negative result: Any sample that shows no Ct value is regarded as negative. Negative control and no template control should have no Ct values.

1.4. Viral antigen detection

Nasal, ocular or genital swabs can be directly smeared onto glass cover-slips, or, following centrifugation, the cell deposit (see Section B.1.1) may be spotted onto cover-slips. These cover-slips are subjected to a standard direct or indirect fluorescent antibody test. In a direct immunofluorescence test, the monospecific antiserum is conjugated to a fluorescent dye e.g. fluorescein isothiocyanate (FITC), whereas in the indirect procedure, the anti-species immunoglobulin secondary antibody is conjugated to a fluorochrome. To obtain reliable results, it is necessary to sample several animals in a herd that have fever and a slight, serous nasal discharge. Smears should be air-dried and fixed in acetone. Smears from nasal swabs from cattle with a purulent or haemorrhagic nasal discharge are often negative (Terpstra, 1979). The advantage of this antigen-detection technique is that it can lead to a same-day diagnosis. However, the sensitivity of this procedure is lower than that of virus isolation (Edwards *et al.*, 1983) or PCR. Positive and negative controls must be included in each test.

Tissues collected at post-mortem can be examined for the presence of BoHV-1 antigen by immunofluorescence analyses of frozen sections. Immunohistochemistry may also be applied for BoHV-1 detection and determination of the antigen location in the tissues. MAbs are increasingly being used for detecting BoHV-1 antigen, leading to enhanced specificity of the test. However, such MAbs must be carefully selected, because they must be directed against conserved epitopes that are present on all isolates of BoHV-1.

Another possibility for direct rapid detection of viral antigen is the use of an enzyme-linked immunosorbent assay (ELISA). Antigen can be captured by MAbs or polyclonal antibodies coated on a solid phase, usually on microplates. Amounts of antigen equivalent to 10^4 – 10^5 TCID₅₀ of BoHV-1 are required in order to obtain reliable positive results. This may not be unrealistically high, because titres of 10^8 – 10^9 TCID₅₀/ml of nasal fluid can be excreted by cattle 3–5 days after infection with BoHV-1. Sensitivity can be increased by amplification systems (see Edwards & Gitao, 1987).

In contrast to virus isolation, no cell culture facilities are required for direct antigen detection techniques and a laboratory diagnosis can be made within 1 day. The disadvantages are the lower sensitivity of direct antigen detection and the extra requirement to perform additional virus isolation, if the isolate is required for further studies.

Therefore, real-time PCR is the state-of-the-art standard, and antigen detection should only be used if other methods are not available.

1.5. Differentiation of bovine herpesvirus 1 subtypes and of ruminant alphaherpesviruses related to bovine herpesvirus 1

By using appropriate MAbs for immunofluorescence, radioimmunoprecipitation, immunoperoxidase or immunoblot assays, BoHV-1 subtype 1 and subtype 2b can be differentiated (Rijsewijk *et al.*, 1999; Wyler *et al.*, 1989). Restriction endonuclease digestion of viral DNA enables differentiation between BoHV-1 subtypes. RFLP analysis includes extraction of the DNA from virions or from infected cells, digestion of the isolated DNA by restriction endonucleases, and separation of the resulting fragments by agarose gel electrophoresis. Differentiation of the BoHV-1 subtypes 1, 2a and 2b by HindIII endonuclease digestion is based on the molecular weight of three relevant DNA fragments (*I*, *K* and *L*) (Metzler *et al.*, 1985). RFLP techniques are of limited diagnostic value, but may be useful in epidemiological studies. Furthermore, RFLP pattern of virus isolates can be compared with that of live vaccine strains.

When differentiation is required between antigenically and genetically related alphaherpesviruses (BoHV-1, BoHV-5, caprine herpesvirus 1, cervid herpesvirus 1 and 2, elk herpesvirus 1, bubaline herpesvirus 1), improved methods are available using monoclonal antibodies (Keuser *et al.*, 2004) or PCR amplification and sequencing (Ros *et al.*, 1999).

HTS techniques can also be used to reveal the whole genome of BoHV-1 and compare different outbreak strains. The HTS is likely to be used more routinely due to improved technology and protocols. For optimised results, the virus titre should be as high as possible, and purified virus

preparations allow the best sequencing results. See also Chapter 1.1.7 *Standards for high throughput sequencing, bioinformatics and computational genomics*.

1.6. Interpretation of results

The isolation of BoHV-1 from a diseased animal does not unequivocally mean that this virus is the cause of the illness. It may, for instance, be a latent virus that has been reactivated due to stressful conditions. A confirmatory laboratory diagnosis must be made from a group of animals and must be accompanied by seroconversion from negative to positive, or a four-fold or higher increase in BoHV-1-specific antibody titres. Paired serum samples collected 3–4 weeks apart are examined in a serological test for the presence of specific antibodies (see Section B.2).

2. Serological tests

Serological tests can be used for several purposes:

- i) To diagnose an acute infection: paired serum samples from the acute and convalescent stages of infection of the same animals are examined in one test. A seroconversion from negative to positive or a four-fold or higher increase in antibody titres is considered to prove an acute infection.
- ii) To demonstrate absence of infection, for instance, for international trade purposes.
- iii) To determine the prevalence of infection in seroepidemiological studies.
- iv) To support eradication programmes and subsequent surveillance.
- v) For research purposes, for instance, the evaluation of the antibody response after vaccination and challenge infection.

Virus neutralisation (VN) tests (Bitsch, 1978) and various ELISAs (Kramps *et al.*, 1993) are usually used for detecting antibodies against BoHV-1 in serum. Because virus latency is a normal sequel to BoHV-1 infection, the identification of serologically positive animals provides a useful and reliable indicator of infection status. Any animal with antibodies to the virus is considered to be a carrier and potential intermittent excretor of the virus. The only exceptions are calves that have acquired passive colostral antibodies from their dam, and noninfected cattle vaccinated with inactivated vaccines. It has been reported that, under experimental conditions, calves infected under cover of maternal immunity may become serologically negative while carrying a reactivatable latent infection (Lemaire *et al.*, 2000).

In general, BoHV-1 serological tests can be divided into conventional and marker tests. Up to now, the only serological marker tests available are the BoHV-1 gE-antibody blocking ELISAs (Van Oirschot *et al.*, 1997). Animals vaccinated with gE-deleted marker vaccines can be discriminated from field-virus infected animals by a negative serological reaction for gE. For conventional serology, VNT, BoHV1-antibody blocking ELISAs or indirect ELISAs may be used.

For the detection of antibodies in (bulk) milk samples ELISAs, including the gE-ELISA, are mainly used (Wellenberg *et al.*, 1998a), but have some limitations. By testing bulk milk, a positive gB-specific test indicates the presence of several infected animals in the herd (Frankena *et al.*, 1997). With the gE-blocking ELISA, bulk milk gives a positive reaction only when more than 10–15% of the herd is infected (Wellenberg *et al.*, 1998b) although the sensitivity can be increased by milk concentration protocols (Schroeder *et al.*, 2012). Consequently, it is not possible to declare a herd to be free from BoHV-1 infection with these tests on the basis of bulk or pooled milk samples, and a negative gE- or gB-ELISA bulk milk test should be followed up with individual blood samples from all cattle in the herd. However, indirect ELISAs optimised for use with bulk milk samples of up to 50 individual cows (or up to 100 animals in BoHV-1-free regions) can indicate reliably the BoHV-1 status of these animals. These test systems are able to detect one weak positive sample in a pool of 50 milk samples or one strong positive milk in a pool composed of 100 samples. For general surveillance purposes, bulk milk tank tests can give an estimate of BoHV-1 prevalence in a herd, an area or country (Nylin *et al.*, 2000). These should be supplemented by serum testing (individual or pooled) from non-milking herds. For monitoring a BoHV-1 status in dairy herds, bulk milk samples of up to 50 (or up to 100 in BoHV-1-free regions) animals should be tested 3–4 times per year with a suitable indirect ELISA. In herds of more than 50 (or 100 in BoHV-1-free regions) cows, several bulks of milk from the animals should be tested. Positive bulk milk results have to be confirmed by testing individual blood or milk samples from all animals that contributed to the positive bulk milk sample.

In an extensive study, tests for the detection of antibodies routinely used by national reference laboratories in Europe were evaluated (Kramps *et al.*, 2004). Twelve reference laboratories from 12 European countries participated in this study. Fifty-three serum samples and 13 milk samples, originating from several countries, were sent in duplicate under code to the participating laboratories. The serum samples included the three European reference sera EU1 (antibody positive), EU2 (antibody weak positive and defined as borderline sample) and EU3

(antibody negative) (Perrin *et al.*, 1994). At that time, it was concluded that VNT and gB-specific ELISAs are the most sensitive tests for the detection of antibodies in serum. However, modern ELISA systems show a clearly improved sensitivity. Owing to the very high sensitivity of the gB-blocking ELISAs, gB-antibody weak positive results can often not be confirmed by alternative test systems (indirect ELISA, VNT). Indirect BoHV-1 ELISAs have now been developed that are also highly sensitive and specific. The results of these ELISAs are comparable with those obtained using gB-blocking ELISAs (Beer *et al.*, 2003).

gE-ELISAs are less sensitive and specific than the conventional test systems. In addition, seroconversion against gE can be delayed, especially in vaccinated animals, and is often not detectable before day 21 to 35 post-infection. A minimum of three different commercial gE-ELISA systems is currently available, allowing the analysis of samples with different gE-ELISAs each with unique characteristics.

2.1. Virus neutralisation

VN tests are performed with various modifications. Tests vary with regard to the virus strain used in the test protocol, the starting dilution of the serum, the virus/serum incubation period (1–24 hours), the type of cells used, the day of final reading and the reading of the end-point (50% versus 100%) (Perrin *et al.*, 1993). Among these variables, the virus/serum incubation period has the most profound effect on the sensitivity of the VNT. A 24-hour incubation period may score up to 16-fold higher antibody titres than a 1-hour incubation period (Bitsch, 1978), and is recommended where maximum sensitivity is required (e.g. for international trade purposes). Various bovine cells or cell lines are suitable for use in the VN test, including secondary bovine kidney or testis cells, cell strains of bovine lung or tracheal cells, or the established MDBK cell line.

2.1.1. Suitable protocol for a VN test

- i) Inactivate sera, including control standard sera, for 30 minutes in a water bath at 56°C.
- ii) Make doubling dilutions of test sera in cell culture medium. Start with undiluted serum and continue to 1/1024 horizontally in a 96-well flat-bottomed cell-culture grade microtitre plate, at least three wells per dilution and 50 µl volumes per well. Dilutions of a positive control serum, and of weak positive and negative internal control sera, are also included in the test. An extra well with undiluted test serum is used for toxicity control of sera.
- iii) Add 50 µl per well of BoHV-1 stock at a dilution in culture medium calculated to provide 100–200 TCID₅₀ per well. In the toxicity control wells, add 50 µl of culture medium in place of virus. Add 100 µl of culture medium to ten empty wells for cell controls.
- iv) Make at least four tenfold dilutions of the residual virus stock (back titration) in culture medium, using 50 µl per well and at least four wells per dilution.
- v) Incubate the plates for 24 hours at 37°C.
- vi) Add 100 µl per well of the cell suspension at 3 × 10⁴ cells per well.
- vii) Incubate the plates for 3–5 days at 37°C.
- viii) Read the plates microscopically for CPEs. Validate the test by checking the back titration of virus (which should give a value of 100 TCID₅₀ with a permissible range of 30–300 TCID₅₀), the control sera and the cell control wells. The positive control serum should give a titre of ± 1 twofold dilution (±0.3 log₁₀ units) from its target value. The weak positive serum should be positive. The negative serum should give no neutralisation (equivalent to a final dilution of 1/2 at the neutralisation stage). In the cell control wells, the monolayers should be intact.
- ix) The test serum results are expressed as the reciprocal of the dilution of serum that neutralised the virus in 50% of the wells. If 50% of the wells with undiluted serum neutralised the virus, the (initial dilution) titre is read as 1 (1/2 using the final dilution convention). If all the undiluted and 50% of the wells with 1/2 diluted serum neutralised the virus, the (initial dilution) titre is 2 (final dilution 1/4). For qualitative results, any neutralisation at a titre of 1 or above (initial dilution convention) is considered to be positive. If cytotoxicity is observed in the control wells, the sample is reported to be toxic (no result) unless neutralisation of the virus without cytotoxicity is observed at higher dilutions and a titre can be read without ambiguity. Where cytotoxicity of a serum interferes with the interpretation of the neutralising activity of the sample, changing the medium in the wells of the lowest two or three dilutions 16–24 hours after the addition of cells may remove the cytotoxic effects.

2.2. Enzyme-linked immunosorbent assay

ELISAs for the detection of antibody against BoHV-1 are widely used, however a standard procedure for ELISA has not been established. Several types of ELISA are commercially available, including indirect and blocking ELISAs, some of which are also suitable for detecting antibodies in milk (Kramps *et al.*, 2004). For reasons of standardisation in a country or state, it may be desirable to compare the quality of the kits and to perform batch release tests by previously defined criteria in a national reference laboratory, before it is used by other laboratories in the country.

There are a number of variations in the ELISA procedures. The most common are: antigen preparation and coating, the dilution of the test sample, the incubation period of antigen and test sample, and the substrate/chromogen solution. Before being used routinely, an ELISA should be validated with respect to sensitivity, specificity and reproducibility (see chapter 1.1.6). For this purpose, a comprehensive panel of well defined (e.g. by VN test) strong positive, weak positive and negative sera has to be tested. However, it is recommended to use commercially available ELISAs that have been shown to perform better than home-made assays (Kramps *et al.*, 2004).

2.2.1. Indirect enzyme-linked immunosorbent assay

The principle of an indirect ELISA is based on the binding of BoHV-1-specific antibodies present in the test sample to immobilised BoHV-1 antigen. The bound antibodies are detected using enzyme-labelled anti-bovine immunoglobulin antiserum. The presence of antibodies in the test sample will result in colour development after addition of the substrate/chromogen solution. This test principle is the most suitable for individual and pooled milk samples.

2.2.2. Blocking enzyme-linked immunosorbent assay

The principle of a blocking or competitive ELISA is based on blocking the binding of an enzyme-labelled BoHV-1 antiserum or anti-BoHV-1 MAb to immobilised antigen by antibodies in the test sample. The presence of antibodies in the test sample results in reduced colour development after addition of the substrate/chromogen solution. An example of a gB blocking ELISA procedure is given below:

- i) Prepare the antigen by growing BoHV-1 in cell cultures. When extensive CPE is observed, cells and medium are frozen at -20°C . After thawing, the resulting cellular lysate is centrifuged for 4 hours at 8500 *g*. The virus-containing pellet is suspended in a small volume of phosphate buffered saline (PBS), cooled on ice and disrupted using an ultrasonic disintegrator. The antigen preparation is then centrifuged for 10 minutes at 800 *g*, and inactivated by adding detergent (final concentration of 0.5% Nonidet P 40). The antigen preparation is used at an appropriate dilution to coat the microtitre plates. Many alternative methods of antigen production are described in the published literature.
- ii) Coat the microtitre plates with antigen by adding 100 μl of diluted antigen (in 0.05 M carbonate buffer, pH 9.6) to each well. Seal the plates with tape, incubate at 37°C overnight, and store at -20°C .
- iii) Before the test is performed, wash the plates with 0.05% Tween 80. Add 100 μl negative serum (fetal calf serum, FCS), 100 μl of each of the serum test samples and 100 μl of positive, weak positive and negative control sera. Usually, serum samples are tested undiluted. Shake, seal the plates and incubate overnight at 37°C . If false-positive reactions are suspected (e.g. when epidemiologically implausible results are generated), it is recommended to retest such sera after heating for 30 minutes at 56°C following one freeze–thaw cycle.
- iv) Wash the plates thoroughly and add 100 μl of an anti-BoHV-1-gB-monoclonal antibody/horseradish peroxidase conjugate at a predetermined dilution, and incubate again for 1 hour at 37°C . The monoclonal antibody must be selected carefully for its specificity to gB of BoHV-1.
- v) Wash the plates and add freshly prepared substrate/chromogen solution (e.g. 0.05 M citric acid buffer, pH 4.5, containing 2,2'-azino-bis-[3-ethylbenzothiazoline]-6-sulphonic acid [ABTS; 0.55 mg/ml] and a 3% solution of freshly added H_2O_2 [5 $\mu\text{l}/\text{ml}$]), and incubate for the appropriate time (1–2 hours at room temperature).
- vi) Measure the absorbance of the plates on a microplate photometer at 405 nm.
- vii) Calculate for each test sample the blocking percentage $[(\text{OD}_{\text{FCS}} - \text{OD}_{\text{test sample}})/\text{OD}_{\text{FCS}} \times 100\%]$

- vii) A test sample is considered to be positive if it has a blocking percentage of e.g. 50% or higher. The test is valid if the positive and weak positive control sera are positive and the negative control serum reacts negatively. The acceptable limits for control and cut-off values must be determined for the individual assay.

2.3. Standardisation

In each serological test, appropriate controls of strong positive, weak positive and negative serum should be included. A scientific group in Europe, initiated by the group of artificial insemination veterinarians of the European Union (EU), has agreed on the use of a strong positive (EU1), a weak positive (EU2) and negative serum (EU3) for standardisation of BoHV-1 tests in laboratories that routinely examine samples from artificial insemination centres (Perrin *et al.*, 1994). These sera have been adopted as OIE international standards for BoHV-1 tests and are available in limited quantities at the OIE Reference Laboratories for IBR/IPV⁵. Tests that are suitable for certifying individual animals prior to movement (VN or ELISA) must be capable of scoring both the strong and weak positive standards (or secondary national standards of equivalent potency) as positive. Because of the limited availability of the international standard sera, there is a need to prepare a new extended panel of reference lyophilised serum (and milk) samples taken from infected as well as from vaccinated animals. This panel should be used to validate newly developed tests and to harmonise tests between laboratories. Additional reference sera are available in limited quantities from the OIE Reference Laboratories (e.g. R1, R2 and R3 as positive, weak positive and very weak positive standard sera from the OIE Reference Laboratory in Germany).

2.4. Nonspecific reactivity in BoHV-1-serology and 'pseudo-vaccines'

Nonspecific reactivity of sera in the BoHV-1-ELISAs should be taken into consideration, and is more often seen for the marker test than for the conventional serology. There are several reasons for nonspecific reactions:

- i) Batch variation of the ELISA used;
- ii) Samples were tested very early after collection (freshness phenomenon);
- iii) Samples tested by gE ELISA were collected within 4 weeks after vaccination with a marker vaccine (vaccination phenomenon);
- iv) Bad specimen quality (e.g. haemolysed samples).

Therefore the following measures should be considered:

- i) Validation of each test batch, and batch release tests have to be implemented;
- ii) Specimens should be stored at 4°C and should not be tested before 24–48 hours after sample collection;
- iii) Samples should be subjected to a freeze–thaw cycle (–20°C); in some cases a subsequent heat inactivation (30 minutes/56°C) may eliminate nonspecific reactions of serum samples;
- iv) Cattle should not be serologically tested for BoHV-1 prior to 4 weeks after any vaccination;
- v) gE-ELISAs should not be used for classification of unvaccinated animals.

In IBR/IPV-free regions, implausible singleton reactors are occasionally detected in gB blocking and indirect ELISAs, which cause problems concerning the status of both the animal and the affected herd. It has been suggested that BoHV-2 infection could be the cause of this cross reactivity (Böttcher *et al.*, 2012). Interestingly, the gE-ELISAs are the most BoHV-1-specific serological tests available and cross reactivity with non-BoHV-1 herpesviruses is very low in these ELISAs. This is especially critical in BoHV-1-free regions where single animals with cross reactivity are detected and might be misinterpreted as BoHV-1 incursion into the herd. Therefore, in free regions, gE-ELISAs and VN tests should be used to further verify such singleton reactors. One recommendation is to repeat testing of those animals after 28 days in a gE-ELISA using a lower cut-off (e.g. positive/negative of 0.95) to increase the sensitivity. In the case of two negative gE-ELISA results, the animal is not classified as BoHV-1-positive, but it is recommended to slaughter the animal as diagnostic problems with other test systems may still occur (e.g. positive bulk milk results of the affected herd).

5 FLI, Greifswald-Insel Riems, Germany and APHA, Weybridge, UK.

C. REQUIREMENTS FOR VACCINES

1. Background

1.1. Rationale and intended use of the product

Several attenuated and inactivated BoHV-1 vaccines are currently available. The vaccine strains have usually undergone multiple passages in cell culture. Some of the vaccine virus strains have a temperature-sensitive phenotype, i.e. they do not replicate at temperatures of 39°C or higher. Attenuated vaccines are administered intranasally or intramuscularly. Inactivated vaccines contain high levels of inactivated virus or portions of the virus particle (glycoproteins) supplemented with an adjuvant to stimulate an adequate immune response. Inactivated vaccines are given intramuscularly or subcutaneously. Vaccination against BoHV-1 is used to protect animals from the clinical outcome of infection, and as an aid in control and eradication programmes.

Marker or DIVA (differentiation of infected from vaccinated animals) vaccines are now available in various countries. These attenuated or inactivated marker vaccines are based on deletion mutants (deletion of gE) or on a subunit of the virion, for instance glycoprotein D. The use of such marker vaccines in conjunction with companion diagnostic tests allows the distinction between infected and vaccinated cattle (DIVA principle), and provides the basis for BoHV-1 eradication programmes in countries or regions with a high prevalence of field-virus infected animals. Intensive vaccination programmes can reduce the prevalence of infected animals (Bosch *et al.*, 1998; Mars *et al.*, 2001), which could be monitored by using an appropriate diagnostic test. In situations where it is economically justifiable, the residual infected animals could be slaughtered, resulting in a region free from BoHV-1. Control and eradication of BoHV-1 was started in some countries in the early 1980s. Different policies have been used due to differences in herd prevalence, breeding practices and disease eradication strategies. To date, in the EU, only gE-deleted DIVA vaccines (live as well as killed) have been marketed and used for control or eradication programmes.

Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine production*. The guidelines given here and in chapter 1.1.8 are of general nature and may be supplemented by national and regional requirements.

2. Outline of production and minimum requirements for conventional vaccines

2.1. Characteristics of the seed

2.1.1. Biological characteristics

The vaccine is prepared using a seed-lot-like system. Origin, passage history and storage conditions of the master seed virus (MSV) must be recorded. A virus identity test must be performed on the MSV. The seed lot contains BoHV-1 strains have to be attenuated to yield a live vaccine strain. The strains can be attenuated by multiple passages in cell cultures, by adapting virus to grow at low temperatures (temperature-sensitive mutants), or by genetic engineering, for example, by deleting one or more viral genes (e.g. the BoHV-1 glycoprotein E) that are nonessential for replication. There should be some means of distinguishing the live vaccine virus from field viruses (for example temperature-specific growth patterns or restriction fragment length polymorphisms). Strains used for the preparation of inactivated vaccines need not be attenuated. The seed lot must be free from contaminants.

2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

The seed lot is tested for absence of extraneous viruses and absence from contamination with bacteria, fungi or mycoplasma. The following extraneous viruses should be specifically excluded in BoHV-1 vaccines: adenovirus, Akabane virus, Schmallenberg virus, bovine coronavirus, bovine herpesviruses 2, 4 and 5, bovine parvovirus, bovine respiratory syncytial virus, bovine viral diarrhoea virus and atypical pestiviruses, bovine rotavirus, vaccinia virus, and the viruses of Aujeszky's disease, bluetongue, bovine ephemeral fever, bovine leukaemia, bovine papilloma, bovine papular stomatitis, cowpox, foot and mouth disease, lumpy skin disease, malignant catarrhal fever, parainfluenza 3, rabies, rinderpest, and vesicular stomatitis. As bovine viral diarrhoea virus (either CPE or non-CPE) has regularly been found to be a contaminant of vaccines, special attention should be paid to the absence of BVDV. In addition, new atypical pestiviruses (e.g. HoBi or HoBi-like) have to be taken into consideration as possible contaminants.

2.2. Method of manufacture

2.2.1. Procedure

The cells used for vaccine production are prepared using a master-cell-lot system. The virus should be cultured on established cell lines that have been shown to be suitable for vaccine production, for example the Madin–Darby bovine kidney (MDBK) cell line. The history of the cell line must be known. The cell line must be free from extraneous agents and may be tested for tumorigenicity.

2.2.2. Requirements for substrates and media

All substances used for the manufacture of vaccines must be free from contaminants. Cells should be used that are not further than 20 passages from the master cell stock. The seed virus should not be more than five passages from the MSV. Genetically engineered vaccine virus strains are treated in the same way as conventionally attenuated vaccine virus strains. When sufficient cells are grown, infection of the cell line with the vaccine virus takes place. The addition of antibiotics is normally restricted to cell culture fluids. The supernatant fluid is harvested at times when the virus (antigen) production peaks. For live vaccines, the supernatant is clarified, mixed with a stabiliser, freeze-dried and bottled. For the production of classical inactivated vaccines, the supernatant is homogenised before the inactivating agent is added in order to ensure proper inactivation. After the inactivation procedure, a test for ensuring complete inactivation of the virus is carried out. The test should include at least two passages in cells. The inactivated virus suspension is then mixed with an adjuvant and bottled. The manufacture of vaccines must comply with guidelines for Good Manufacturing Practice (GMP) and local regulations such as European Pharmacopoeia or United States Code of Federal Regulations (9CFR).

2.2.3. In-process controls

Working cell seed and working virus seed must have been shown to be free from contaminants. The cells must show inconspicuous morphology before being inoculated with virus. The CPE is checked during cultivation. Uninoculated control cells must have retained their morphology until the time of harvesting. A virus titration is performed on the harvested supernatant. During the production of inactivated vaccines, tests are performed to ensure inactivation. The final bulk must be tested for freedom from contaminants.

2.2.4. Final product batch tests

The following tests must normally be performed on each batch. Example guidelines for performing batch control can be found in EU directives, the European Pharmacopoeia and 9CFR.

i) Sterility/purity

Bacteria, fungi, mycoplasma and extraneous viruses must not be present. Tests for sterility and freedom from contamination of biological materials intended for veterinary use may be found in chapter 1.1.9.

ii) Safety

For inactivated vaccines, a twofold dose of vaccine, and for live vaccines, a tenfold dose of vaccine, must not produce adverse effects in young BoHV-1 seronegative calves.

iii) Batch potency

It is sufficient to test one representative batch for efficacy, as described in Section C.2.3.2. In the case of live vaccines, the virus titre of each batch must be determined and must be not higher than 1/10 of the dose at which the vaccine has been shown to be safe, and no lower than the minimum release titre. In the case of inactivated vaccines, the potency is tested using another validated method, for instance, efficacy assessment in calves.

2.3. Requirements for authorisation

2.3.1. Safety requirements

i) Target and non-target animal safety

A quantity of virus equivalent to ten doses of vaccine should (a) not induce significant local or systemic reactions in young calves; (b) not cause fetal infection or abortion, and (c) not

revert to virulence during five serial passages in calves. For inactivated vaccine, a double dose is usually administered. The reversion to virulence test is not applicable to inactivated vaccines.

ii) Reversion-to-virulence for attenuated/live vaccines

The selected final vaccine strain should not revert to virulence during a minimum of five serial passages in calves.

iii) Environmental consideration

Attenuated vaccine strains should not be able to perpetuate autonomously in a cattle population ($R_0 < 1$).

2.3.2. Efficacy requirements

i) For animal production

This must be shown in vaccination challenge experiments under laboratory conditions. Example guidelines are given in a monograph of the European Pharmacopoeia (Third Edition (1997)). Briefly, the vaccine is administered to ten 2–3-month-old BoHV-1 seronegative calves. Two calves are kept as controls. All the calves are challenged intranasally 3 weeks later with a virulent strain of BoHV-1 that gives rise to typical clinical signs of a BoHV-1 infection. The vaccinated calves should show no or only very mild signs. The maximum (peak) virus titre in the nasal mucus of vaccinated calves should be at least 100 times lower than that in control calves. The virus excretion period should be at least 3 days shorter in vaccinated than in control calves.

An efficacious BoHV-1 vaccine should induce protective immunity for at least 1 year, although many existing vaccines have not been tested to this standard.

ii) For control and eradication

In addition to the above-mentioned criteria, BoHV-1-vaccines for control and eradication should be marker vaccines (e.g. gE-deleted vaccines) allowing the differentiation of infected from vaccinated animals (DIVA-strategy). Several gE-deleted vaccines (inactivated preparations as well as modified live vaccines) are commercially available.

2.3.3. Stability

For live vaccines, virus titrations should be carried out 3 months beyond the indicated shelf life. In addition, tests for determining moisture content, concentrations of preservatives, and pH are performed. For inactivated vaccines, the viscosity and stability of the emulsion are also tested.

The efficacy of preservatives should be demonstrated. The concentration of the preservative and its persistence throughout shelf life should be checked. The concentration must be in conformity with the limits set for the preservative.

3. Vaccines based on biotechnology

3.1. Vaccines available and their advantages

Glycoprotein E (gE)-deleted inactivated and modified live vaccines are available that are based on recombinant strains. The vaccines are comparable to other gE-deleted vaccines and are licensed by European Medicines Agency (EMA) for use in the EU.

Additional recombinant vaccines like gD-subunits or genetically engineered deletion mutants of BoHV-1 (e.g. with deletions of gE and/or gG) are described and available as prototypes.

Advantages of BoHV-1 vaccines based on biotechnology could be the possibility of additional marker features for the differentiation of infected from vaccinated animals (DIVA; e.g. gB-antibody-ELISAs for gD-subunit vaccines or gG-antibody-ELISAs for the respective deletion mutants).

3.2. Special requirements for biotechnological vaccines, if any

Recombinant vaccines, which are destined for use in the EU have to be licensed by EMA.

REFERENCES

- ABRIL C., ENGELS M., LIMAN A., HILBE M., ALBINI S., FRANCHINI M., SUTER M. & ACKERMANN M. (2004). Both viral and host factors contribute to neurovirulence of bovine herpesviruses 1 and 5 in interferon receptor-deficient mice. *J. Virol.*, **78**, 3644–3653.
- ASHBAUGH S.E., THOMPSON K.E., BELKNAP E.B., SCHULTHEISS P.C., CHOWDHURY S. & COLLINS J.K. (1997). Specific detection of shedding and latency of bovine herpesvirus 1 and 5 using a nested polymerase chain reaction. *J. Vet. Diagn. Invest.*, **9**, 387–394.
- BEER M., KÖNIG P., SCHIELKE G. & TRAPP S. (2003). Markerdiagnostik in der Bekämpfung des Bovinen Herpesvirus vom Typ 1: Möglichkeiten und Grenzen. *Berl. Münch. Tierärztl. Wschr.*, **116**, 183–191.
- BÖTTCHER J., BOJE J., JANOWETZ B., ALEX M., KÖNIG P., HAGG M., GÖTZ F., RENNER K., OTTERBEIN C., MAGES J., MEIER N. & WITTKOWSKI G. (2012). Epidemiologically non-feasible singleton reactors at the final stage of BoHV1 eradication: serological evidence of BoHV2 cross-reactivity. *Vet. Microbiol.*, **159**, 282–290.
- BITSCH V. (1978). The P37/24 modification of the infectious bovine rhinotracheitis virus serum neutralization test. *Acta Vet. Scand.*, **19**, 497–505.
- BOSCH J.C., DE JONG M.C.M., FRANKEN P., FRANKENA K., HAGE J.J., KAASHOEK M.J., MARIS-VELDHUIS M.A., NOORDHUIZEN J.P.T.M., VAN DER POEL W.H.M., VERHOEFF J., WEERDMEESTER K., ZIMMER G.M. & VAN OIRSCHOT J.T. (1998). An inactivated gE-negative marker vaccine and an experimental gD-subunit vaccine reduce the incidence of bovine herpesvirus 1 infections in the field. *Vaccine*, **16**, 265–271.
- BRUNNER D., ENGELS M., SCHWYZER M. & WYLER R. (1988). A comparison of three techniques for detecting bovine herpesvirus type 1 (BHV-1) in naturally and experimentally contaminated bovine semen. *Zuchthygiene (Berlin)*, **23**, 1–9.
- DEKA D., MAITI RAMNEEK N.K. & OBEROI M.S. (2005). Detection of bovine herpesvirus-1 infection in breeding bull semen by virus isolation and polymerase chain reaction. *Rev. sci. tech. Off. int. Epiz.*, **24**, 1085–1094.
- EDWARDS S., CHASEY D. & WHITE H. (1983). Experimental infectious bovine rhinotracheitis: comparison of four antigen detection methods. *Res. Vet. Sci.*, **34**, 42–45.
- EDWARDS S. & GITAO G.C. (1987). Highly sensitive antigen detection procedures for the diagnosis of infectious bovine rhinotracheitis: amplified ELISA and reverse passive haemagglutination. *Vet. Microbiol.*, **13**, 135–141.
- EDWARDS S., WHITE H. & NIXON P. (1990). A study of the predominant genotypes of bovid herpesvirus 1 isolated in the U.K. *Vet. Microbiol.*, **22**, 213–223.
- EUROPEAN PHARMACOPOEIA, 3RD EDITION (1997). Monograph 0696: Live freeze dried vaccine for infectious bovine rhinotracheitis. Council of Europe, Strasbourg, France.
- FRANKENA K., FRANKEN P., VANDEHOEK J., KOSKAMP G. & KRAMPS J.A. (1997). Probability of detecting antibodies to bovine herpesvirus 1 in bulk milk after the introduction of a positive animal on to a negative farm. *Vet. Rec.*, **140**, 90–92.
- FUCHS M., HUBERT P., DETTERER J. & RZIHA H.-J. (1999). Detection of bovine herpesvirus type 1 in blood from naturally infected cattle by using a sensitive PCR that discriminates between wild-type virus and virus lacking glycoprotein E. *J. Clin. Microbiol.*, **37**, 2498–2507.
- GROM J., HOSTNIK P., TOPLAK I. & BARLIC-MAGANJA D. (2006). Molecular detection of BHV-1 in artificially inoculated semen and in the semen of a latently infected bull treated with dexamethasone. *Vet. J.*, **171**, 539–544.
- KAASHOEK M.J., MOERMAN A., MADIC J., RIJSEWIJK F.A.M., QUAK J., GIELKENS A.L.J. & VAN OIRSCHOT J.T. (1994). A conventionally attenuated glycoprotein E-negative strain of bovine herpesvirus type 1 is an efficacious and safe vaccine. *Vaccine*, **12**, 439–444.
- KEUSER V., SCHYNTS F., DETRY B., COLLARD A., ROBERT B., VANDERPLASSCHEN A., PASTORET P.-P. & THIRY E. (2004). Improved antigenic methods for differential diagnosis of bovine, caprine, and cervine alphaherpesviruses related to bovineherpesvirus 1. *J. Clin. Microbiol.*, **42**, 1228–1235.

- KRAMPS J.A., BANKS M., BEER M., KERKHOFS P., PERRIN M., WELLENBERG G.J. & VAN OIRSCHOT J.T. (2004). Evaluation of tests for antibodies against bovine herpesvirus 1 performed in national reference laboratories in Europe. *Vet Microbiol.*, **102**, 169–181.
- KRAMPS J.A., QUAK S., WEERDMEESTER K & VAN OIRSCHOT J.T. (1993). Comparative study on sixteen enzyme-linked immunosorbent assays for the detection of antibodies to bovine herpesvirus 1 in cattle. *Vet. Microbiol.*, **35**, 11–21.
- LEMAIRE M., WEYNANTS V., GODFROID J., SCHYNTS F., MEYER G., LETESSON J.J. & THIRY E. (2000). Effects of bovine herpesvirus type 1 infection in calves with maternal antibodies on immune response and virus latency. *J. Clin. Microbiol.*, **38**, 1885–1894.
- LOVATO L., INMAN M., HENDERSON G., DOSTER A. & JONES C. (2003). Infection of cattle with a bovine Herpesvirus 1 strain that contains a mutation in the latency-related gene leads to increased apoptosis in trigeminal ganglia during the transition from acute infection to latency. *J. Virol.*, **77**, 4848–4857.
- MAGYAR G., TANYI J., HORNYAK A. & BATHA A. (1993). Restriction endonuclease analysis of Hungarian bovine herpesvirus isolates from different clinical forms of IBR, IPV and encephalitis. *Acta Vet. Hung.*, **41**, 159–170.
- MARS M.H., DE JONG M.C.M., FRANKEN P. & VAN OIRSCHOT J.T. (2001). Efficacy of a live glycoprotein E-negative bovine herpesvirus 1 vaccine in cattle in the field. *Vaccine*, **19**, 1924–1930.
- MASRI S.A., OLSON W., NGUYEN P.T., PRINS S. & DEREGT D. (1996). Rapid detection of bovine herpesvirus 1 in the semen of infected bulls by a nested polymerase chain reaction assay. *Can. J. Vet. Res.*, **60**, 100–107.
- MECHOR G.D., ROUSSEAU C.G., RADOSTITS O.M., BABIUK L.A. & PETRIE L. (1987). Protection of newborn calves against fatal multisystemic infectious bovine rhinotracheitis by feeding colostrum from vaccinated cows. *Can. J. Vet. Res.*, **51**, 452–459.
- METZLER A.E., MATILE H., GASSMANN U., ENGELS M. & WYLER R. (1985). European isolates of bovine herpesvirus 1: a comparison of restriction endonuclease sites, polypeptides, and reactivity with monoclonal antibodies. *Arch. Virol.*, **85**, 57–69.
- MOORE S., GUNN M. & WALLS D. (2000). A rapid and sensitive PCR-based diagnostic assay to detect bovine herpesvirus 1 in routine diagnostic submissions. *Vet. Microbiol.*, **75**, 145–153.
- NYLIN B., STROGER U. & RONSHOLT L. (2000). A retrospective evaluation of a bovine herpesvirus-1 (BHV-1) antibody ELISA on bulk-tank milk samples for classification of the BHV-1 status of Danish dairy herds. *Prev. Vet. Med.*, **47**, 91–105.
- PARSONSON I.M. & SNOWDON W.A. (1975). The effect of natural and artificial breeding using bulls infected with, or semen contaminated with, infectious bovine rhinotracheitis virus. *Aust. Vet. J.*, **51**, 365–369.
- PERRIN B., BITSCH V., CORDIOLI P., EDWARDS S., ELOIT M., GUERIN B., LENIHAN P., PERRIN M., RONSHOLT L., VAN OIRSCHOT J.T., VANOPDENBOSCH E., WELLEMANS G., WIZIGMANN G. & THIBIER M. (1993). A European comparative study of serological methods for the diagnosis of infectious bovine rhinotracheitis. *Rev. sci. tech. Off. int. Epiz.*, **12**, 969–984.
- PERRIN B., CALVO T., CORDIOLI P., COUDERT M., EDWARDS S., ELOIT M., GUERIN B., KRAMPS J.A., LENIHAN P., PASCHALERI E., PERRIN M., SCHON J., VAN OIRSCHOT J.T., VANOPDENBOSCH E., WELLEMANS G., WIZIGMANN G. & THIBIER M. (1994). Selection of European Union standard reference sera for use in the serological diagnosis of infectious bovine rhinotracheitis. *Rev. sci. tech. Off. int. Epiz.*, **13**, 947–960.
- RIJSEWIJK F.A., KAASHOEK M.J., LANGEVELD J.P., MELOEN R., JUDEK J., BIENKOWSKA-SZEWCZYK K., MARIS-VELDHUIS M.A. & VAN OIRSCHOT J.T. (1999). Epitopes on glycoprotein C of bovine herpesvirus-1 (BHV-1) that allow differentiation between BHV-1.1 and BHV-1.2 strains. *J. Gen. Virol.*, **80**, 1477–1483.
- ROLA J., POLAK M. & ZMUDZINSKI J. (2003). Amplification of DNA of BHV 1 isolated from semen of naturally infected bulls. *Bull. Vet. Inst. Pulawy*, **47**, 71–75.
- ROS C., RIQUELME M.E., OHMAN FORSLUND K. & BELAK S. (1999). Improved detection of five closely related ruminant alphaherpesviruses by specific amplification of viral genome sequences. *J. Virol. Methods*, **83**, 55–65.

- SANTURDE G., SILVA N.D., VILLARES R., TABARES E., SOLANA A., BAUTISTA J.M., CASTRO J.M. & DA SILVA N. (1996). Rapid and high sensitivity test for direct detection of bovine herpesvirus-1 genome in clinical samples. *Vet. Microbiol.*, **49**, 81–92.
- SCHROEDER C., HORNER S., BÜRGER N., ENGEMANN C., BANGE U., KNOOP E.V. & GABERT J. (2012). Improving the sensitivity of the IBR-gE ELISA for testing IBR marker vaccinated cows from bulk milk. *Berl. Munch. Tierarztl. Wochenschr.*, **125**, 290–296.
- SCHYNTS F., BARANOWSKI E., LEMAIRE M. & THIRY E. (1999). A specific PCR to differentiate between gE negative vaccine and wildtype bovine herpesvirus type 1 strains. *Vet. Microbiol.*, **66**, 187–195.
- SMITS C.B., VAN MAANEN C., GLAS R.D, DE GEE A.L., DIJKSTRAB T, VAN OIRSCHOT J.T. & RIJSEWIJK F.A. (2000). Comparison of three polymerase chain reaction methods for routine detection of bovine herpesvirus 1 DNA in fresh bull semen. *J. Virol. Methods*, **85**, 65–73.
- TERPSTRA C. (1979). Diagnosis of infectious bovine rhinotracheitis by direct immunofluorescence. *Vet. Q.*, **1**, 138–144.
- THIRY J., KEUSER V., MUYLKENS B., MEURENS F., GOGEV S., VANDERPLASSCHEN A. & THIRY E. (2006). Ruminant alphaherpesviruses related to bovine herpesvirus 1. *Vet. Res.*, **37**, 169–190.
- VAN ENGELENBURG F.A., MAES R.K., VAN OIRSCHOT J.T. & RIJSEWIJK F.A. (1993). Development of a rapid and sensitive polymerase chain reaction assay for detection of bovine herpesvirus type 1 in bovine semen. *J. Clin. Microbiol.*, **31**, 3129–3135.
- VAN ENGELENBURG F.A.C., VAN SCHIE F.W., RIJSEWIJK F.A.M. & VAN OIRSCHOT J.T. (1995). Excretion of bovine herpesvirus 1 in semen is detected much longer by PCR than by virus isolation. *J. Clin. Microbiol.*, **33**, 308–312.
- VAN OIRSCHOT J.T., KAASHOEK M.J., MARIS-VELDHUIS M.A., WEERDMEESTER K. & RIJSEWIJK F.A.M. (1997). An enzyme-linked immunosorbent assay to detect antibodies against glycoprotein gE of bovine herpesvirus 1 allows differentiation between infected and vaccinated cattle. *J. Virol. Methods*, **67**, 23–34.
- VAN OIRSCHOT J.T., STRAVER P.J., VAN LIESHOUT J.A.H., QUAK J., WESTENBRINK F. & VAN EXSEL A.C.A. (1993). A subclinical infection of bulls with bovine herpesvirus type 1 at an artificial insemination centre. *Vet. Rec.*, **132**, 32–35.
- VILCEK S., NETTLETON P.F., HERRING J.A. & HERRING A.J. (1994). Rapid detection of bovine herpesvirus 1 (BHV 1) using the polymerase chain reaction. *Vet. Microbiol.*, **42**, 53–64.
- WANG J., O'KEEFE J., ORR D., LOTH L., BANKS M., WAKELEY P., WEST D., CARD R., IBATA G., VAN MAANEN K., THOREN P., ISAKSSON M. & KERKHOF P. (2008). An international inter-laboratory ring trial to evaluate a real-time PCR assay for the detection of bovine herpesvirus 1 in extended bovine semen. *Vet. Microbiol.*, **126**, 11–19.
- WEIBLEN R., KREUTZ L., CANABOROO T.F., SCHUCH L.C. & REBELATTO M.C. (1992). Isolation of bovine herpesvirus 1 from preputial swabs and semen of bulls with balanoposthitis. *J. Vet. Diag. Invest.*, **4**, 341–343.
- WELLENBERG G.J., VERSTRATEN E.R.A.M., MARS M.H. & VAN OIRSCHOT J.T. (1998a). Detection of bovine herpesvirus 1 glycoprotein E antibodies in individual milk samples by enzyme-linked immunosorbent assays. *J. Clin. Microbiol.*, **36**, 409–413.
- WELLENBERG G.J., VERSTRATEN E.R.A.M., MARS M.H. & VAN OIRSCHOT J.T. (1998b). ELISA detection of antibodies to glycoprotein E of bovine herpesvirus 1 in bulk milk samples. *Vet Rec.*, **142**, 219–220.
- WERNIKE K., HOFFMANN B., KALTHOFF D., KÖNIG P. & BEER M. (2011). Development and validation of a triplex real-time PCR assay for the rapid detection and differentiation of wild-type and glycoprotein E-deleted vaccine strains of Bovine herpesvirus type 1. *J. Virol. Methods*, **174** (1–2), 77–84.
- WIEDMANN M., BRANDON R., WAGNER P., DUBOVI E.J. & BATT C.A. (1993). Detection of bovine herpesvirus-1 in bovine semen by a nested PCR assay. *J. Virol. Methods*, **44**, 129–140.
- WYLER R., ENGELS M. & SCHWYZER M. (1989). Infectious bovine rhinotracheitis/vulvovaginitis (BHV1). In: *Herpesvirus Diseases of Cattle, Horses and Pigs*, Wittmann G., ed. Kluwer Academic Publishers, Boston, USA, 1–72.

XIA J.Q., YASON C.V. & KIBENGE F.S. (1995). Comparison of dot blot hybridization, polymerase chain reaction, and virus isolation for detection of bovine herpesvirus-1 (BHV-1) in artificially infected bovine semen. *Can. J. Vet. Res.*, **59**, 102–109.

YASON C.V., HARRIS L.M., MCKENNA P.K., WADOWSKA, D. & KIBENAGE F.S.B. (1995). Establishment of conditions for the detection of bovine herpesvirus-1 by polymerase chain reaction using primers in the thymidine kinase region. *Can. J. Vet. Res.*, **59**, 94–101.

*
* *

NB: There are OIE Reference Laboratories for infectious bovine rhinotracheitis/infectious pustular vulvovaginitis (please consult the OIE Web site:

<https://www.oie.int/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

Please contact the OIE Reference Laboratories for any further information on diagnostic tests, reagents and vaccines for infectious bovine rhinotracheitis/infectious pustular vulvovaginitis

NB: FIRST ADOPTED IN 1990 AS INFECTIOUS BOVINE RHINOTRACHEITIS. MOST RECENT UPDATES ADOPTED IN 2017.